Previous 10 | Next 10 |
Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024 PR Newswire – Late-Breaking Abstracts Containing Data From the Full Narcolepsy Type 1 Cohort From the ALKS 2680 Phase 1b Study and Vibrance-1 Phase 2 Study Design Accepted for Poster Presentations ...
2024-05-25 12:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips As we delve deeper into 2024, biotech stocks are commanding the attention of growth-focused investors. Despite facing volatility and regulatory challenges in recent years, biotech is poised...
2024-05-23 13:30:04 ET Piper Sandler analyst issues BUY recommendation for ALKS on May 23, 2024 12:00PM ET. The previous analyst recommendation was Buy. ALKS was trading at $24.085 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current a...
2024-05-22 09:30:09 ET Cantor Fitzgerald analyst issues OVERWEIGHT recommendation for ALKS on May 22, 2024 07:26AM ET. The previous analyst recommendation was Overweight. ALKS was trading at $24.34 at issue of the analyst recommendation. The overall analyst consensus : B...
2024-05-17 08:27:04 ET Summary Alkermes is positioned for outperformance in the pharmaceutical sector due to its conservative cash-heavy balance sheet and high-margin business model. The company focuses on therapies for alcohol dependence, opioid dependence, schizophrenia, bipolar...
2024-05-15 14:20:39 ET Summary This monthly article series shows aggregate industry metrics in the healthcare sector. All healthcare subsectors are overvalued based on my metrics. Pharmaceuticals/biotechnology has the lowest scores in both value and quality. Invesco S&P 50...
Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences PR Newswire ̶ Results from Long-Term Safety Study and Data from Healthcare Resource Utilization Research Offer Insights into Treatment Experiences for ...
2024-05-02 07:10:00 ET Summary Q1 earnings growth expectations have sharply declined more than usual as we enter earnings season. Over the past three months, Q1 growth projections have been adjusted downward by 21.5 percentage points, settling at a current year-over-year decline o...
Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk PR Newswire DUBLIN , May 2, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) has completed the previously announced sale of its development and manufacturing facility in Athlone, Irela...
2024-05-01 11:20:07 ET Alkermes plc (ALKS) Q1 2024 Earnings Conference Call May 01, 2024 08:00 AM ET Company Participants Sandra Coombs - Senior Vice President, Corporate Affairs and Investor Relations Blair Jackson - Chief Operating Officer Todd Nichols - Chief ...
News, Short Squeeze, Breakout and More Instantly...
Alkermes plc (ALKS) is expected to report $0.64 for Q2 2024 Acerinox ADR (ANIOY) is expected to report for Q2 2024 Allegion plc (ALLE) is expected to report $1.77 for Q2 2024 Deutsche Bank AG (DB) is expected to report $0.43 for Q2 2024 Pathward Financial Inc. (CASH) is expected t...
Alkermes plc Reports Second Quarter 2024 Financial Results PR Newswire — Second Quarter Revenues of $399.1 Million — — Net Sales of Proprietary Products Increased Approximately 16% Year-Over-Year — — GAAP Net Income from C...
2024-07-22 10:45:03 ET Enbridge Inc (ENB) ENB is trading UP for the last 5 days, and it at trading at $36.59 with volume of 731,965 and a one day change of $0.05 (0.14%). Enbridge Inc has a 52-week low of 31.03 and a 52-week high of $38.36. The business's 50-day moving average price...